A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer

Carcinogenesis

Volumn 30, Issue 11, 2009, Pages 1910-1915

  Kulkarni, Diptee A ^a   Vazquez, Alexei ^a,b   Haffty, Bruce G ^a   Bandera, Elisa V ^a   Hu, Wenwei ^a   Sun, Yvonne Y ^a   Toppmeyer, Deborah L ^a   Levine, Arnold J ^a,b   Hirshfield, Kim M ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN MDMX;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE OVEREXPRESSION; GENE STRUCTURE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGE OF ONSET; BREAST NEOPLASMS; CARCINOMA, DUCTAL; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70849123864     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp224     Document Type: Article

References (48)

1. Vogelstein,B. et al. (2000) Surfing the p53 network. Nature, 408, 307-310.
2. Harris,S.L. et al. (2005) The p53 pathway: Positive and negative feedback loops. Oncogene, 24, 2899-2908.
3. Momand,J. et al. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245.
4. Oliner,J.D. et al. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362, 857-860.
5. Honda,R. et al. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420, 25-27.
6. Kubbutat,M.H. et al. (1999) Analysis of the degradation function of Mdm2. Cell Growth Differ., 10, 87-92.
7. Shvarts,A. et al. (1996) MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J., 15, 5349-5357.
8. Jackson,M.W. et al. (2000) MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell. Biol., 20, 1001-1007.
9. Sharp,D.A. et al. (1999) Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem., 274, 38189-38196.
10. Stad,R. et al. (2001) Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep., 2, 1029-1034.
11. Stad,R. et al. (2000) Hdmx stabilizes Mdm2 and p53. J. Biol. Chem., 275, 28039-28044.
12. Linares,L.K. et al. (2003) HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc. Natl Acad. Sci. USA, 100, 12009-12014.
13. Poyurovsky,M.V. et al. (2007) The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J., 26, 90-101.
14. Uldrijan,S. et al. (2007) An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J., 26, 102-112.
15. Donehower,L.A. et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
16. Jones,S.N. et al. (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature, 378, 206-208.
17. Montes de Oca Luna,R. et al. (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature, 378, 203-206.
18. Finch,R.A. et al. (2002) mdmx is a negative regulator of p53 activity in vivo. Cancer Res., 62, 3221-3225.
19. Migliorini,D. et al. (2002) Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol., 22, 5527-5538.
20. Parant,J. et al. (2001) Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet., 29, 92-95.
21. Chavez-Reyes,A. et al. (2003) Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res., 63, 8664-8669.
22. Montes de Oca Luna,R. et al. (1997) Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat. Genet. 16, 336-337.
23. Steinman,H.A. et al. (2004) Absence of p21 partially rescues Mdm4 loss and uncovers an antiproliferative effect of Mdm4 on cell growth. Oncogene, 23, 303-306.
24. Steinman,H.A. et al. (2005) Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development. Oncogene 24, 7935-7940.
25. Barboza,J.A. et al. (2008) Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol. Cancer Res., 6, 947-954.
26. Florenes,V.A. et al. (1994) MDM2 gene amplification and transcript levels in human sarcomas: Relationship to TP53 gene status. J. Natl Cancer Inst., 86, 1297-1302.
27. He,J. et al. (1994) Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosomes Cancer 11, 91-96.
28. Watanabe,T. et al. (1994) The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood, 84, 3158-3165.
29. Riemenschneider,M.J. et al. (1999) Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res., 59, 6091-6096.
30. Bartel,F. et al. (2005) Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int. J. Cancer, 117, 469-475.
31. Laurie,N.A. et al. (2006) Inactivation of the p53 pathway in retinoblastoma. Nature, 444, 61-66.
32. Rosen,E.M. et al. (2003) BRCA1 gene in breast cancer. J. Cell. Physiol., 196, 19-41.
33. Tonin,P.N. (2000) Genes implicated in hereditary breast cancer syndromes. Semin. Surg. Oncol., 18, 281-286.
34. Bond,G.L. et al. (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res., 66 5104-5110.
35. Bond,G.L. et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
36. Hu,W. et al. (2007) A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res., 67, 2757-2765.
37. Atwal,G.S. et al. (2009) Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc. Natl Acad. Sci. USA, 106, 10236-10241.
38. Nichols,H.B. et al. (2006) From menarche to menopause: Trends among US Women born from 1912 to 1969. Am. J. Epidemiol., 164 1003-1011.
39. Millikan,R.C. et al. (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res. Treat., 109, 123-139.
40. Bond,G.L. et al. (2005) A single nucleotide polymorphism in the MDM2 gene: From a molecular and cellular explanation to clinical effect. Cancer Res., 65, 5481-5484.
41. Kakarala,M. et al. (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J. Clin. Oncol. 26, 2813-2820.
42. Polyak,K. (2007) Breast cancer: Origins and evolution. J. Clin. Invest., 117, 3155-3163.
43. Alli,E. et al. (2009) Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res., 69, 3589-3596.
44. Jin,Y. et al. (2008) MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2. Mol. Cell. Biol., 28, 1218-1229.
45. LeBron,C. et al. (2006) Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J., 25, 1196-1206.
46. Rallapalli,R. et al. (1999) A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J. Biol. Chem., 274, 8299-8308.
47. Giglio,S. et al. (2005) Identification of an aberrantly spliced form of HDMX in human tumors: A new mechanism for HDM2 stabilization. Cancer Res., 65, 9687-9694.
48. Cardon,L.R. et al. (2001) Association study designs for complex diseases. Nat. Rev. Genet., 2, 91-99.